858 Therapeutics, an innovative biotechnology and drug discovery company specializing in oncology, has successfully raised $50 million in its latest funding round. This significant capital infusion will propel the company's mission to develop a proprietary portfolio of small molecule drugs that target novel therapeutic pathways, especially in cancers notoriously resistant to existing treatments. Founded by a seasoned team with a proven track record in pharmaceutical and biotech drug discovery, 858 Therapeutics leverages cutting-edge knowledge in epigenetics, single-cell genomics, and innate immunity to pave the way for breakthrough therapies. The firm is strategically headquartered in San Diego, California鈥攁 thriving biotech hub鈥攚hile also maintaining lab operations in New York City, ensuring access to premier scientific talent and research collaborations across both coasts. The funds raised will not only advance 858's ongoing research projects into promising therapeutic candidates but will also enhance the company鈥檚 capabilities in clinical development. With an unwavering commitment to transforming the landscape of cancer treatment, the team at 858 Therapeutics is equipped with the resources to significantly impact the healthcare landscape and improve outcomes for patients suffering from difficult-to-treat cancers. As they embark on this next phase, the company remains poised to lead with innovation and expertise in the ever-evolving field of oncology.
858 Therapeutics Secures $50 Million in Series B Funding to Advance Oncology Drug Discovery
Recently funded 路 $50.0M Series bBiotechnology and Drug Discovery
Get the full 858 Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
